ERBB2 and breast carcinoma: Trastuzumab‐conjugated MZ1 nanoparticles (MZ1–ACNPs) showed significantly enhanced cytotoxic effects in HER2+ breast cancer cells and overcame natural MZ1 resistance in resistant cell lines, while antibody conjugation prevented protein corona formation and maintained delivery specificity [411].